^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    NAV3 (Neuron Navigator 3 )

    i
    Other names: NAV3, Neuron Navigator 3, Pore Membrane And/Or Filament Interacting Like Protein 1, Unc-53 Homolog 3, STEERIN3, POMFIL1, Unc53H3, Pore Membrane And/Or Filament-Interacting-Like Protein 1, Steerin-3, Steerin 3
    3ms
    Comparison of the Effects of Sodium Orthovanadate and Sodium Metavanadate on the Growth and Survival of DU-145 Prostate Cancer Cells. (PubMed, Biol Trace Elem Res)
    This inhibition was attributed to apoptosis and necrosis, as well as cell cycle arrest at the G1/S checkpoint. The findings suggest that sodium metavanadate and sodium orthovanadate are potential anticancer agents against prostate cancer, effective at low concentrations.
    Journal
    |
    NAV3 (Neuron Navigator 3 )
    8ms
    Identification of Candidate Genes for Endometriosis in a Three-Generation Family with Multiple Affected Members Using Whole-Exome Sequencing. (PubMed, Biomedicines)
    We identified novel candidate genes for endometriosis in a multigenerational affected family, supporting a polygenic model of the disease. Our study is an exploratory family-based WES study, and replication and functional studies are warranted to confirm these preliminary findings.
    Journal
    |
    MLH1 (MutL homolog 1) • NAV3 (Neuron Navigator 3 )
    9ms
    IMOP-Cancer: identifying mutation order pairs impacting cancer phenotypes. (PubMed, Brief Bioinform)
    Shared mutation pairs across cancers also showed distinct effects on cancer phenotype. Our study highlights the importance of mutation order in cancer progression and diversity, offering new insights into the temporal dynamics of co-occurring mutations and paving the way for personalized treatment strategies and improved diagnosis.
    Journal
    |
    TP53 (Tumor protein P53) • CSMD3 (CUB And Sushi Multiple Domains 3) • NAV3 (Neuron Navigator 3 )
    9ms
    FAT1 mutation-related signature predicts survival risk and tumor immunogenicity in lung adenocarcinoma. (PubMed, Front Genet)
    Based on the immunotherapeutic patients, an improved immune checkpoint blockade treatment prognosis and an elevated response rate are also observed in the low-risk signature group. In summary, Our identified FAT1 mutation-related risk signature shows potential for assessing LUAD clinical outcomes, tumor immunogenicity, and immunotherapy effectiveness, providing valuable insights for LUAD clinical practice.
    Journal • Tumor mutational burden • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • KEAP1 (Kelch Like ECH Associated Protein 1) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • CDH1 (Cadherin 1) • FAT1 (FAT atypical cadherin 1) • NAV3 (Neuron Navigator 3 )
    |
    TP53 mutation
    9ms
    GWAS meta-analysis identifies five susceptibility loci for endometrial cancer. (PubMed, EBioMedicine)
    Our large study extends the number of genome-wide significant risk loci identified for endometrial carcinoma by about one-third and proposes a role of NAV3 as a tumour suppressor in this common cancer.
    Retrospective data • Journal
    |
    ATF7IP (Activating Transcription Factor 7 Interacting Protein) • PPARG (Peroxisome Proliferator Activated Receptor Gamma) • NAV3 (Neuron Navigator 3 )
    11ms
    Single-cell and bulk transcriptome sequencing identifies circadian rhythm disruption and cluster-specific clinical insights in colorectal tumorigenesis. (PubMed, Discov Oncol)
    This study not only provide new insights into the assessment of CR status in CRC patients but also develop a prognosis model based on CR-related genes, offering a new tool for personalized risk assessment in CRC.
    Journal
    |
    MSI (Microsatellite instability) • NAV3 (Neuron Navigator 3 ) • RAB3B (Ras-related protein Rab-3B)
    |
    MSI-H/dMMR
    1year
    Development of a prognostic model based on the ceRNA network in Triple-Negative Breast cancer. (PubMed, PeerJ)
    This study developed a novel prognostic model based on a ceRNA network analysis, highlighting the critical role of circRNAs and the MAPK signaling pathway in TNBC progression. These findings offer valuable insights into potential biomarkers for TNBC prognosis and reveal promising therapeutic targets for improving patient outcomes.
    Journal
    |
    GFRA1 (GDNF Family Receptor Alpha 1) • NAV3 (Neuron Navigator 3 ) • CDC7 (Cell Division Cycle 7) • NPTX1 (Neuronal Pentraxin 1)
    over1year
    Explorations of novel MDR-related hub genes and the potential roles TRIM9 played in drug-resistant hepatocellular carcinoma. (PubMed, Int J Biol Macromol)
    Inhibiting TRIM9 caused a decrease in the IC50 of doxorubicin (DOX), and significant increases in the intracellular uptake, retention and absorption of DOX in HepG2/ADR cells. These findings may provide new insights into the mechanism of MDR development. The MDR-related hub genes, especially TRIM9 may be targeted therapeutically to enhance the prognosis of patients with drug-resistant HCC.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • ABCB6 (ATP Binding Cassette Subfamily B Member 6 (Langereis Blood Group)) • NAV3 (Neuron Navigator 3 ) • FLNC (Filamin C) • TRIM9 (Tripartite Motif Containing 9)
    |
    doxorubicin hydrochloride
    over1year
    Microtubule-associated NAV3 regulates invasive phenotypes in glioblastoma cells. (PubMed, Brain Pathol)
    Consistently, we observed increased NAV3 expression in cells migrating along blood vessels in mouse xenografts. Overall, our results shed light on the role of NAV3 in glioblastoma invasion, providing insights into this lethal aspect of glioblastoma behavior.
    Journal
    |
    NAV3 (Neuron Navigator 3 )
    over1year
    Differential prognostic impact and potential molecular mechanisms of PCDHGA12 expression in lung adenocarcinoma and squamous cell carcinoma. (PubMed, Int Immunopharmacol)
    These genetic and immunological differences may account for the significant prognostic disparity of PCDHGA12 levels between LUAD and LUSC. Further experimental studies are essential to validate these associations and investigate potential targeted and immunotherapeutic strategies.
    Journal • IO biomarker
    |
    KEAP1 (Kelch Like ECH Associated Protein 1) • CD8 (cluster of differentiation 8) • HMGB1 (High Mobility Group Box 1) • SPTA1 (Spectrin Alpha) • TNFRSF18 (TNF Receptor Superfamily Member 18) • NAV3 (Neuron Navigator 3 ) • CDH23 (Cadherin Related 23) • SFTPA1 (Surfactant Protein A1)
    over1year
    Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance. (PubMed, Hum Genomics)
    The present study identified several putative somatic and germline genetic events with prognostic potential for colorectal cancer that should undergo functional characterization.
    Journal
    |
    KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • LRP1B (LDL Receptor Related Protein 1B) • FBXW7 (F-Box And WD Repeat Domain Containing 7) • ERBB4 (erb-b2 receptor tyrosine kinase 4) • FAT4 (FAT Atypical Cadherin 4) • RYR1 (Ryanodine Receptor 1) • GLI3 (GLI Family Zinc Finger 3) • COL6A3 (Collagen Type VI Alpha 3 Chain) • NAV3 (Neuron Navigator 3 ) • RIF1 (Replication Timing Regulatory Factor 1) • TENM4 (Teneurin Transmembrane Protein 4) • ABCA1 (ATP Binding Cassette Subfamily A Member 1) • FLG (Filaggrin) • RYR3 (Ryanodine Receptor 3) • ABCA13 (ATP Binding Cassette Subfamily A Member 13) • TCHH (Trichohyalin)
    |
    5-fluorouracil
    2years
    Gene Fusions in Aggressive Testicular Leydig Cell Tumors Likely Represent Events Secondary to Genomic Instability without a Driver Role (USCAP 2024)
    TERT fusions were not identified in this series of LCTs, with 2 aggressive metastasizing LCTs harboring non-recurrent NAV3::ASB8 and RAB3IP::TAFA2. These structural variants have not been reported previously and likely represent events secondary to genomic instability without a clear pathogenic role (PMID: 34103665). Whole transcriptome analysis is under way to elucidate additional genomic alterations present in aggressive LCTs.
    MDM2 (E3 ubiquitin protein ligase) • NAV3 (Neuron Navigator 3 )
    |
    MDM2 amplification
    |
    TruSight RNA Pan-Cancer Panel